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Abstract
Holoprosencephaly (HPE) is a major structural birth defect of the brain that occurs in 
approximately 1 in 10,000 live births. Although some genetic causes of HPE are known, a 
substantial proportion of cases have an unknown etiology. Due to the low birth prevalence and 
rarity of exposure to many potential risk factors for HPE, few epidemiologic studies have had 
sufficient sample size to examine risk factors. A 2010 review of the literature identified several 
risk factors that had been consistently identified as occurring more frequently among cases of 
HPE, including maternal diabetes, twinning, and a predominance of females, while also 
identifying a number of potential risk factors that had been less widely studied. In this article, we 
summarize a systematic literature review conducted to update the evidence for nongenetic risk 
factors for HPE.
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1 | INTRODUCTION
Holoprosencephaly (HPE) is a major structural birth defect of the brain and is considered 
one of the most frequently occurring brain abnormalities, with a prevalence of 
approximately 1 in 250 conceptions (Matsunaga & Shiota, 1977). However, the birth 
prevalence of HPE is much lower at about 1 in 10,000 live births, indicating a high rate of 
Correspondence: April D. Summers, Division of Congenital and Developmental Disorders, National Center on Birth Defects and 
Developmental Disabilities, Centers for Disease Control and Prevention, 4770 Buford Hwy, MS E86, Chamblee, GA 30341., 
isp3@cdc.gov. 
Publisher's Disclaimer: DISCLAIMER
Publisher's Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the 
official position of the Centers for Disease Control and Prevention.
CONFLICT OF INTEREST
None.
HHS Public Access
Author manuscript
Am J Med Genet C Semin Med Genet. Author manuscript; available in PMC 2019 August 
22.
Published in final edited form as:
Am J Med Genet C Semin Med Genet. 2018 June ; 178(2): 151–164. doi:10.1002/ajmg.c.31614.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
fetal death, which poses a challenge for epidemiologic study of possible risk factors (Orioli 
& Castilla, 2010; Rasmussen, Moore, Khoury, & Cordero, 1996). Case classification and 
ascertainment of HPE is also challenging because there is a continuum of phenotypic 
variation, including mild or asymptomatic presentations that are not always classified as 
HPE (Hahn & Barnes, 2010), and a spectrum of accompanying facial characteristics, such as 
cyclopia, the most severe form of HPE (Orioli & Castilla, 2010). Although some genetic 
causes of HPE have been identified (i.e., single gene disorders and chromosome 
abnormalities) (Roessler & Muenke, 2010), the etiology of many cases of HPE is unknown.
The vast majority of papers in the scientific literature regarding nongenetic risk factors for 
HPE in humans are case reports and small case series, which are important contributions to 
the literature in that they can generate hypotheses for future research. For example, recent 
case reports have described infants with HPE born to mothers with diabetes and a mother 
with alcoholism (Chen et al., 2012; Goswami & Kusre, 2015; Pallangyo et al., 2016). 
However, little inference can be made regarding whether the exposure-birth defect 
correlation observed is due to chance alone because these reports lack an appropriate 
comparison group and cannot account for the background rate of birth defects (Rasmussen, 
Hayes, Jamieson, & O’Leary, 2007).
Likewise, animal studies also provide important contributions to our understanding of 
teratogens. Recent studies have found associations between HPE, alcohol consumption and 
synthetic cannabinoids and evidence of gene-environment interactions with exposure to 
retinoic acid in animal models (Billington et al., 2015; Gilbert et al., 2016; Hong & Krauss, 
2017). Although animal models allow experimental manipulation of exposures and provide 
an opportunity to investigate gene-environment interactions, findings may not be relevant to 
humans (Scialli et al., 2004).
Epidemiologic studies, including case-control studies, cohort studies, and reports from birth 
defects surveillance systems or pregnancy registries, can provide opportunities to evaluate 
risk factors for HPE in humans over time and with appropriate comparison groups. However, 
given the low birth prevalence of HPE and rarity of many exposures of interest, such as 
medication use or infections during pregnancy, few epidemiologic studies have adequate 
sample size, and statistical power to evaluate many potential risk factors. These 
epidemiologic studies are typically retrospective case-control studies that investigate a 
spectrum of risk factors for HPE or are studies of specific risk factors that have included 
HPE as one of many defects studied.
A 2010 review identified four large case-control studies that focused on risk factors for HPE 
and a few other studies that examined factors associated with a range of birth defects 
including HPE (Johnson & Rasmussen, 2010). The most extensively studied risk factor 
identified by the review was maternal diabetes, with numerous studies observing a 
prevalence of pre-existing and gestational diabetes at least twice as high among mothers of 
children with HPE as mothers of controls (Anderson et al., 2005; Correa et al., 2008; Croen, 
Shaw, & Lammer, 2000; Martínez-Frías, Bermejo, Rodríguez-Pinilla, Prieto, & Frías, 1998; 
Orioli & Castilla, 2007). Sex ratio has also been widely studied, with many studies finding 
an excess of females with HPE (Croen et al., 2000; Kallen et al., 1992; Olsen, Hughes, 
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Youngblood, & Sharpe-Stimac, 1997; Orioli & Castilla, 2007; Rasmussen et al., 1996; 
Whiteford & Tolmie, 1996). HPE has also consistently been observed to occur more 
frequently among twins or other multiple births than singletons (Bullen, Rankin, & Robson, 
2001; Miller, Rasmussen, Siega-Riz, Frias, & Honein, 2010; Odent, Le Marec, Munnich, Le 
Merrer, & Bonaïti-Pellie, 1998).
According to the 2010 review, a number of other maternal demographic characteristics and 
exposures have been identified as potential risk factors for HPE, but there was less evidence 
to support these. Epidemiologic studies assessing the use of aspirin and salicylates have had 
inconsistent results, with two studies finding an association with HPE and one that did not 
(Croen et al., 2000; Miller et al., 2010; Orioli & Castilla, 2007). Other factors such as use of 
assisted reproductive technologies and maternal sexually transmitted infections may increase 
the risk of HPE and warrant future study (Croen et al., 2000; Miller et al., 2010).
In the current manuscript, we update the evidence for nongenetic risk factors for HPE based 
on a systematic review of the literature published since the 2010 review was conducted 
(Johnson & Rasmussen, 2010). Given the limited conclusions that can be drawn from case 
reports and animal studies, we have elected to restrict this review to epidemiologic studies.
2 | METHODS
Because studies in which HPE was included as one of many defects under investigation for a 
particular risk factor might be missed in a traditional systematic literature review, we 
conducted our review in multiple phases (Figure 1). We first searched for 
“holoprosencephaly” using Medline (OVID), Embase (OVID), CINAHL (Ebsco), and 
Scopus databases (see Appendix A for full search strategy). We supplemented this with a 
search of full texts in an internal library of publications from the National Birth Defects 
Prevention Study (NBDPS), a case-control study that included rare defects such as HPE. We 
included publications from January 2009 through January 2018. After this first phase 
identified 57 epidemiologic studies and case reports that were potentially of interest, we 
searched for “holoprosencephaly” among the full text of the publications citing and cited by 
these publications. We limited the publications included in this review to those with at least 
five cases of HPE that were not included in the 2010 review paper. The full texts of these 
publications were reviewed and 17 publications were included in this review.
3 | RESULTS
3.1 | National Birth Defects Prevention Study
Between 2009 and January 2018, 14 publications using data from the NBDPS included HPE 
as an outcome of interest (Table 1); however, one previous study of nongenetic risk factors 
for HPE published during this time period was included in the 2010 review and excluded 
from the current review (Miller et al., 2010). The NBDPS was a population-based case-
control study of major birth defects that was conducted for births in 10 U.S. states between 
October 1997 and December 2011. NBDPS methods for recruitment of participants and case 
classification have been described in detail elsewhere (Rasmussen et al., 2003; Reefhuis et 
al., 2015; Yoon et al., 2001). Briefly, NBDPS cases include infants or fetuses with one or 
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more major structural birth defect identified through population-based active case-finding 
surveillance systems in Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey, 
New York, North Carolina, Texas, and Utah. Cases were reviewed by a clinical geneticist, 
classified as isolated or multiple (>1 major unrelated birth defect in separate organ systems), 
and those with single-gene disorders or recognized chromosomal syndromes were excluded 
(Rasmussen et al., 2003). For inclusion, diagnoses of HPE in cases needed to be confirmed 
postnatally, either by imaging studies or post-mortem examination. Liveborn infants without 
major birth defects (controls) were randomly selected from the same ascertainment areas as 
cases using birth certificates or hospital birth records.
Mothers of cases and controls participated in a computer-assisted telephone interview, 
conducted in English or Spanish, between six weeks and 24 months after their expected date 
of delivery. The interview included detailed questions concerning pregnancy history, 
demographic information, and exposures, such as medication use and maternal infections, 
during the time period of three months before conception through the end of pregnancy. 
During the entire study period, the interview participation rate was approximately 65% for 
mothers of controls (n = 11,814) and 67% for mothers of children with HPE (n = 32,187) 
(Reefhuis et al., 2015). Between 1997 and 2011, 321 cases of HPE were ascertained and 181 
mothers were interviewed; this includes cases of isolated HPE and cases with HPE and other 
major birth defects (multiple). Because analyses of NBDPS data were conducted throughout 
the study period and the inclusion criteria for each analysis varied, the number of cases and 
controls included varied. Unless otherwise noted, all NBDPS analyses described in this 
review included both cases of isolated and multiple HPE and exposures occurred during the 
periconceptional period, from one month prior to conception through the third month of 
pregnancy.
Of the 13 NBDPS studies included in this review, the first NBDPS analysis we describe 
included 1997–2003 data, was restricted to mothers without pre-existing diabetes, and found 
no significant association between periconceptional antibiotic use and HPE (Crider et al., 
2009). In an analysis of 1997–2004 data, mothers of children with isolated HPE were more 
than three times more likely than mothers of controls to report a history of thyroid disease, 
although this finding was based on three exposed cases and was not statistically significant 
(Browne et al., 2009). A publication using data from 1997 to 2004 found that mothers of 
children with HPE were more likely than mothers of controls to have reported a genital tract 
infection during the first trimester, although this finding was based on two exposed cases and 
was not statistically significant (Carter et al., 2011). Among women who took a folic acid-
containing multivitamin, maternal diabetes was associated with a ninefold increased risk of 
HPE (adjusted odds ratio (aOR) 9.06; 95% confidence interval (CI): 1.97–41.77); however, 
this finding was based on two exposed cases (Correa et al., 2012). Tinker and colleagues 
found that mothers of infants with HPE were more than twice as likely to report an injury 
than mothers of controls, although this finding was also not statistically significant (Tinker, 
Reefhuis, Dellinger, & Jamieson, 2011).
Three NBDPS analyses used data from 1997 to 2007 and a fourth included data from 2003 
to 2007 from the Utah site only. After excluding women with diabetes and multiple births, 
Gill et al. (2012) found no association between HPE and maternal age. In a 2012 publication 
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examining the association between birth defects and consumption of foods with a high 
glycemic index, among women without diabetes, an increased odds ratio was observed for 
HPE but was not statistically significant (Parker et al., 2012). In a 2016 publication, Dawson 
et al. (2016) found a nearly threefold increase in HPE prevalence among members of twins, 
compared to singletons (aOR 2.7; 95% CI: 1.2–5.8), which remained elevated in analyses 
restricted to women who did not use fertility treatments. In a study of data from the Utah 
NBDPS site, one mother of a child with HPE self-reported cigarette smoking at any time 
during pregnancy, which was not statistically different from mothers of control infants 
(Srisukhumbowornchai, Krikov, & Feldkamp, 2012).
Three later NBDPS analyses included data from 1997 to 2009 (Howley et al., 2016; Hoyt et 
al., 2016; Michalski et al., 2015), and one used data from the entire study period of 1997–
2011 (Howley et al., 2017). In a 2015 study of male/female sex ratios, a significant 
predominance of females was found among the cases with HPE compared to controls (0.62; 
95% CI: 0.44–0.87) (Michalski et al., 2015). This finding remained significant in a sub-
analysis restricted to isolated cases. In an analysis examining the association between 
maternal autoimmune disease and birth defects (excluding mothers with pregestational 
diabetes), one exposed case of HPE was reported among 134 total cases, a slightly lower 
proportion of exposure than in the controls (Howley et al., 2016). In a study of maternal 
periconceptional secondhand tobacco smoke exposure in the home, workplace or school, 
exposure was slightly less common among mothers of children with HPE than controls, after 
excluding cases and controls from multiple births and mothers reporting active smoking or 
pregestational diabetes (Hoyt et al., 2016). Lastly, in a 2017 publication, use of thyroid 
hormones was significantly higher among mothers of children with HPE than among 
mothers of controls (aOR 2.48; 95% CI 1.13–5.44), based on seven exposed cases; the 
analysis remained statistically significant when restricted to isolated cases of HPE (Howley 
et al., 2017).
3.2 | Other epidemiologic studies of HPE
One of the largest studies of HPE to date compared cases with isolated cyclopia to cases 
with associated malformations and those with chromosomal syndromes (Table 2) (Orioli et 
al., 2011). This study included data from 1968 to 2006 from 20 surveillance systems in 25 
countries that were part of the International Clearinghouse of Birth Defects Surveillance and 
Research. Information on phenotype, genetic testing, and selected demographic and prenatal 
characteristics was provided. All diagnostic information were reported as verbatim 
descriptions and were centrally classified. The authors classified 97 isolated cases of 
cyclopia, 79 cases as having chromosomal syndromes, and 81 cases with malformations not 
usually considered part of the HPE spectrum. Of the isolated cases, 60.8% were female, a 
higher percentage than among cases with other malformations (53.1%) or those with 
chromosomal syndromes (51.9%), although these differences were not statistically 
significant. The authors also observed a higher birth prevalence of cyclopia among older 
mothers, but this was not statistically significant. Other characteristics such as parity, history 
of spontaneous abortion, plurality, and parental age difference were not significantly 
different for isolated cases compared to cases with other malformations or chromosomal 
syndromes.
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Two additional publications since 2009 have examined the association between HPE and sex 
ratio (Sokal, Tata, & Fleming, 2014; Tennant, Samarasekera, Pless-Mulloli, & Rankin, 
2011). A 2011 publication used 1985–2003 data from the Northern Congenital Abnormality 
Survey, which collected diagnostic and demographic data for all birth defects, including live 
births and fetal deaths, in several counties in the North of England, United Kingdom 
(Tennant et al., 2011). Multiple births and cases associated with a known teratogen were 
excluded. Cases of HPE (including arhinencephaly) included 14 males and 22 females. The 
relative risk of HPE for males compared to females was not statistically significant when 
compared to the general population. A second U.K.-based study used data from 1990 to 
2010 from The Health Improvement Network, an anonymized database of primary care 
records covering approximately 6% of the U.K. population (Sokal et al., 2014). The study 
population included all children in the database born during the study period who were 
registered with their general practice before their first birthday (n = 794,169). This study 
also found a predominance of females among cases of arhinencephaly/HPE, but that finding 
was also not statistically significant.
Lastly, a case-control study from 2012 examined a number of potential risk factors for 
nonsyndromic HPE using data from the Winnipeg Children’s Hospital Section of Genetics 
and Metabolism in Manitoba, Canada (Vaz et al., 2012). Cases were live births, 
terminations, and stillbirths between January 1990 and September 2001 that had radiologic 
or autopsy confirmation or strongly suggestive clinical sequence of HPE. Controls were 
from the same database and matched on gender and nearest birthdate. If the control selected 
had (a) a midline craniofacial or structural central nervous system anomaly or (b) multiple 
birth defects and a strongly suspected structural central nervous system anomaly, they were 
excluded and the next eligible person was selected as the control. In total, 47 patients with 
HPE were identified and 47 matched controls were selected; 24 of the cases with HPE were 
determined to be part of a syndrome. The final analysis included 23 cases of nonsyndromic 
HPE and all 47 controls. Significant positive associations with HPE were observed for 
having an Aboriginal parent, either mother or father, and having a family history of a 
midline facial defect. While the authors reported that mothers of children with HPE were 
nearly seven times more likely than mothers of controls to report pre-existing diabetes, the 
study only included three exposed cases and one exposed control and the finding did not 
reach statistical significance. Other factors that were observed to have elevated odds ratios 
were based on small numbers and were not statistically significant; these included low 
socioeconomic status and having had a previous stillbirth or a previous neonatal death.
4 | DISCUSSION
The majority of the studies examining risk factors for nonsyndromic HPE that have been 
published since 2009 have used data from the NBDPS, which was well positioned to provide 
data for these analyses as a result of the large sample size and diversity of topics included in 
the maternal interview. However, even in the NBDPS, most analyses included small numbers 
of exposed cases, and findings were often not statistically significant. NBDPS publications 
added evidence to support previous findings of an association between HPE and diabetes, 
twinning, and sex ratio.
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When considering potential risk factors for birth defects, assessment of the biologic 
plausibility of the findings is important. Maternal diabetes is a risk factor for a large number 
of birth defects (Gabbay-Benziv, Reece, Wang, & Yang, 2015), including HPE. Several 
mechanisms have been proposed to explain the effects of maternal hyperglycemia as a cause 
of birth defects, including increased oxidative stress, hypoxia, apoptosis, and epigenetic 
changes (Ornoy, Reece, Pavlinkova, Kappen, & Miller, 2015). Multivitamin supplements 
might attenuate the risk for some diabetes-associated birth defects (Correa, Botto, Liu, 
Mulinare, & Erickson, 2003; Correa et al., 2012); however, diabetes was a strong risk factor 
for HPE, even among women who were taking folic acid containing supplements (Correa et 
al., 2012). A better understanding of these mechanisms could lead to future measures to 
prevent birth defects among women with diabetes.
Twinning has also been associated with several different types of birth defects (Weber & 
Sebire, 2010), including HPE. It has been hypothesized that early structural defects (such as 
HPE) in monozygotic twins might represent cleavage disorders of the midline field (Opitz & 
Gilbert, 1982; Suslak, Mimms, Desposito, Opitz, & Reynolds, 1987).
The reason for the female predominance among HPE cases is unclear. Female embryos 
might be more susceptible to perturbations that cause HPE or male embryos might be more 
likely to be lost through spontaneous abortion. A large proportion of embryos with HPE are 
lost prenatally (Matsunaga & Shiota, 1977); however, an equal sex ratio among fetuses 
identified prenatally at 16–36 weeks’ gestation (Berry, Gosden, Snijders, & Nicolaides, 
1990) suggests that losses at this later stage in pregnancy do not occur more frequently 
among males.
The association between thyroid hormone use and HPE observed in data from the NBDPS 
needs to be replicated in other studies. Whether the observed association is related to use of 
thyroid hormone, or to the underlying condition for which thyroid hormone treatment is 
used, or is due to chance is unknown. However, thyroid hormone is necessary for 
development of the fetal nervous system (Schroeder & Privalsky, 2014), so the association 
could be biologically plausible.
HPE is a rare and serious birth defect that often results in pregnancy loss, which makes it 
challenging to identify nongenetic risk factors. Studies with a small number of exposed 
cases result in unstable effect estimates and wide confidence intervals, making it difficult to 
distinguish true risk factors from findings observed by chance. To better understand risk 
factors for HPE, data sets with large numbers of cases and sufficient statistical power are 
needed. Because HPE has a wide spectrum of phenotypes and is often associated with a 
chromosomal abnormality or single gene disorder, careful clinical review and classification 
are also essential to create well-defined outcome categories. In addition, incorporation of 
information on genetic factors is important to permit the study of gene-environment 
interaction.
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APPENDIX A
Search Strategy and Results of Systematic Review
Database Strategy Run date Records
Medline 
(OVID) 
1946-
Holoprosencephaly 2/15/2018 59
AND
Case* OR epidemiolog* OR report* OR inciden* OR occurrence OR 
surveillance OR Diabetes OR diabetic* OR drug* OR substance abuse* 
OR medication* OR prescription* OR prescribe* OR nutrition* OR 
maternal health OR (mother* ADJ2 health) OR side effect* OR adverse 
reaction* OR adverse effect* OR adverse event* OR hypertension OR 
blood pressure OR complication* OR exposure* OR expose* OR risk* 
OR factor* OR non-genetic OR nongenetic OR non-syndromic OR 
nonsyndromic OR environmental OR (maternal ADJ2 (illness* OR 
disease*)) OR sociodemographic* OR demographic* OR alcohol* OR 
ethanol OR teratogen* OR hyperglycemi* OR infection* OR CMV OR 
cytomegalovirus OR rubella OR herpes OR virus* OR syphilis OR 
influenza OR fever OR STI* OR STD* OR chlamydia OR anemia OR 
supplement* OR salicylate* OR sulfasalazine OR aspirin OR 
acetaminophen OR advanced age OR smoking OR smoked OR tobacco 
OR antibiotic* OR penicillin* OR ampicillin OR trimethoprim OR sulfa-
methoxazole OR hormone* OR progesterone OR contraceptive* OR 
progesto-gen* OR birth control OR assisted reproduct* OR cholesterol 
OR statin* OR lovastatin OR methotrexate OR tranexamic acid OR 
chloriazepoxide OR imipramine OR lithium OR dimenhydrinate OR 
fertility OR obesity OR BMI OR diet* OR education* OR income OR 
socioeconomic* Or cancer* OR epilepsy OR epileptic OR antiepileptic* 
OR anticonvulsant* OR acne OR retinoic acid
Limit 2009 ;
Embase 
(OVID) 
1947-
Holoprosencephaly 2/15/2018 116 – 58 
duplicates = 
58 unique 
items
AND
Case* OR epidemiolog* OR report* OR inciden* OR occurrence OR 
surveillance OR Diabetes OR diabetic* OR drug* OR substance abuse* 
OR medication* OR prescription* OR prescribe* OR nutrition* OR 
maternal health OR (mother* ADJ2 health) OR side effect* OR adverse 
reaction* OR adverse effect* OR adverse event* OR hypertension OR 
blood pressure OR complication* OR exposure* OR expose* OR risk* 
OR factor* OR non-genetic OR nongenetic OR nonsyndromic OR 
nonsyndromic OR environmental OR (maternal ADJ2 (illness* OR 
disease*)) OR sociodemographic* OR demographic* OR alcohol* OR 
ethanol OR teratogen* OR hyperglycemi* OR infection* OR CMV OR 
cytomegalovirus OR rubella OR herpes OR virus* OR syphilis OR 
influenza OR fever OR STI* OR STD* OR chlamydia OR anemia OR 
supplement* OR salicylate* OR sulfasalazine OR aspirin OR 
acetaminophen OR advanced age OR smoking OR smoked OR tobacco 
OR antibiotic* OR penicillin* OR ampicillin OR trimethoprim OR sulfa-
methoxazole OR hormone* OR progesterone OR contraceptive* OR 
progesto-gen* OR birth control OR assisted reproduct* OR cholesterol 
OR statin* OR lovastatin OR methotrexate OR tranexamic acid OR 
chloriazepoxide OR imipr-amine OR lithium OR dimenhydrinate OR 
fertility OR obesity OR BMI OR diet* OR education* OR income OR 
socioeconomic* Or cancer* OR epilepsy OR epileptic OR antiepileptic* 
OR anticonvulsant* OR acne OR retinoic acid
Limit 2009 ;
CINAHL 
(Ebsco)
Holoprosencephaly 02/15/2018 8–6 
duplicates = 
2 unique 
items
AND
Case* OR epidemiolog* OR report* OR inciden* OR occurrence OR 
surveillance OR Diabetes OR diabetic* OR drug* OR “substance 
abuse*” OR medication* OR prescription* OR prescribe* OR nutrition* 
OR “maternal health” OR (mother* N2 health) OR “side effect*” OR 
“adverse reaction*” OR “adverse effect*” OR “adverse event*” OR 
hypertension OR blood pressure OR complication* OR exposure* OR 
expose* OR risk* OR factor* OR non-genetic OR nonge-netic OR non-
syndromic OR nonsyndromic OR environmental OR (maternal N2 
(illness* OR disease*)) OR sociodemographic* OR demographic* OR 
alcohol* OR ethanol OR teratogen* OR hyperglycemi* OR infection* 
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Database Strategy Run date Records
OR CMV OR cytomega-lovirus OR rubella OR herpes OR virus* OR 
syphilis OR influenza OR fever OR STI* OR STD* OR chlamydia OR 
anemia OR supplement* OR salicylate* OR sul-fasalazine OR aspirin 
OR acetaminophen OR advanced age OR smoking OR smoked OR 
tobacco OR antibiotic* OR penicillin* OR ampicillin OR trimethoprim 
OR sulfamethoxazole OR hormone* OR progesterone OR contraceptive* 
OR progestogen* OR “birth control” OR “assisted reproduct*” OR 
cholesterol OR statin* OR lovastatin OR methotrexate OR tranexamic 
acid OR chloriazepoxide OR imipramine OR lithium OR dimenhydrinate 
OR fertility OR obesity OR BMI OR diet* OR education* OR income 
OR socioeconomic* Or cancer* OR epilepsy OR epileptic OR 
antiepileptic* OR anticonvulsant* OR acne OR “retinoic acid”
Limit 2009 ; exclude Medline records
Cochrane 
library
Holoprosencephaly:ti,ab 02/15/2018 0
AND
(Case* OR epidemiolog* OR report* OR inciden* OR occurrence OR 
surveillance OR Diabetes OR diabetic* OR drug* OR “substance 
abuse*” OR medication* OR prescription* OR prescribe* OR nutrition* 
OR “maternal health” OR (mother* NEAR/2 health) OR “side effect*” 
OR “adverse reaction*” OR “adverse effect*” OR “adverse event*” OR 
hypertension OR blood pressure OR complication* OR exposure* OR 
expose* OR risk* OR factor* OR non-genetic OR nonge-netic OR non-
syndromic OR nonsyndromic OR environmental OR (maternal NEAR/2 
(illness* OR disease*)) OR sociodemographic* OR demographic* OR 
alcohol* OR ethanol OR teratogen* OR hyperglycemi* OR infection* 
OR CMV OR cytomegalovirus OR rubella OR herpes OR virus* OR 
syphilis OR influenza OR fever OR STI* OR STD* OR chlamydia OR 
anemia OR supplement* OR salicylate* OR sulfasalazine OR aspirin OR 
acetaminophen OR advanced age OR smoking OR smoked OR tobacco 
OR antibiotic* OR penicillin* OR ampicillin OR trimethoprim OR 
sulfamethoxazole OR hormone* OR progesterone OR contraceptive* OR 
progestogen* OR “birth control” OR “assisted reproduct*” OR 
cholesterol OR statin* OR lovastatin OR methotrexate OR tranexamic 
acid OR chloriazepoxide OR imipramine OR lithium OR dimenhydrinate 
OR fertility OR obesity OR BMI OR diet* OR education* OR income 
OR socioeconomic* Or cancer* OR epilepsy OR epileptic OR 
antiepileptic* OR anticonvulsant* OR acne OR “retinoic acid”):ti,ab
Limit 2009 ;
Scopus Non-genetic risk factors for holoprosencephaly cited by 02/15/2018 0
OR
TITLE-ABS-KEY(Holoprosencephaly AND (Case* OR epidemiolog* 
OR report* OR inciden* OR occurrence OR surveillance OR Diabetes 
OR diabetic* OR drug* OR “substance abuse*” OR medication* OR 
prescription* OR prescribe* OR nutrition* OR “maternal health” OR 
(mother* W/2 health) OR “side effect*” OR “adverse reaction*” OR 
“adverse effect*” OR “adverse event*” OR hypertension OR “blood 
pressure” OR complication* OR exposure* OR expose* OR risk* OR 
factor* OR non-genetic OR nongenetic OR non-syndromic OR 
nonsyndromic OR environmental OR (maternal W/2 illness*) OR 
(maternal W/2 disease*) OR sociodemographic* OR demographic* OR 
alcohol* OR ethanol OR teratogen* OR hyperglycemi* OR infection* 
OR CMV OR cytomegalovirus OR rubella OR herpes OR virus* OR 
syphilis OR influenza OR fever OR STI* OR STD* OR chlamydia OR 
anemia OR supplement* OR salicylate* OR sulfasalazine OR aspirin OR 
acetaminophen OR advanced age OR smoking OR smoked OR tobacco 
OR antibiotic* OR penicillin* OR ampicillin OR trimethoprim OR 
sulfamethoxazole OR hormone* OR progesterone OR contraceptive* OR 
progestogen* OR “birth control” OR “assisted reproduct*” OR 
cholesterol OR statin* OR lovastatin OR methotrexate OR tranexamic 
acid OR chloriazepoxide OR imipramine OR lithium OR dimenhydrinate 
OR fertility OR obesity OR BMI OR diet* OR education* OR income 
OR socioeconomic* Or cancer* OR epilepsy OR epileptic OR 
antiepileptic* OR anticonvulsant* OR acne OR “reti-noic acid”)) AND 
NOT INDEX(medline) AND NOT INDEX(embase)
Limit 2009 ;
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Database Strategy Run date Records
Medline 
(OVID) 
1946-
Holoprosencephaly 1/11/2018 465
AND
Case* OR epidemiolog* OR report* OR inciden* OR occurrence OR 
surveillance OR Diabetes OR diabetic* OR drug* OR substance abuse* 
OR medication* OR prescription* OR prescribe* OR nutrition* OR 
maternal health OR (mother* ADJ2 health) OR side effect* OR adverse 
reaction* OR adverse effect* OR adverse event* OR hypertension OR 
blood pressure OR complication* OR exposure* OR expose* OR risk* 
OR factor* OR non-genetic OR nongenetic OR nonsyndromic OR 
nonsyndromic OR environmental OR (maternal ADJ2 (illness* OR 
disease*)) OR sociodemographic* OR demographic* OR alcohol* OR 
ethanol OR teratogen* OR hyperglycemi* OR infection* OR CMV OR 
cytomegalovirus OR rubella OR herpes OR virus* OR syphilis OR 
influenza OR fever OR STI* OR STD* OR chlamydia OR anemia OR 
supplement* OR salicylate* OR sulfasalazine OR aspirin OR 
acetaminophen OR advanced age OR smoking OR smoked OR tobacco 
OR antibiotic* OR penicillin* OR ampicillin OR trimethoprim OR 
sulfamethoxazole OR hormone* OR progesterone OR contraceptive* OR 
progestogen* OR birth control OR assisted reproduct* OR cholesterol 
OR statin* OR lovastatin OR methotrexate OR tranexamic acid OR 
chloriazepoxide OR imipramine OR lithium OR dimenhydrinate OR 
fertility OR obesity OR BMI OR diet* OR education* OR income OR 
socioeconomic* Or cancer* OR epilepsy OR epileptic OR antiepileptic* 
OR anticonvulsant* OR acne OR retinoic acid
Limit 2010- ;
Embase 
(OVID) 
1947-
Holoprosencephaly 1/11/2018 137 – 22 
duplicates = 
115 unique 
items
AND
Case* OR epidemiolog* OR report* OR inciden* OR occurrence OR 
surveillance OR Diabetes OR diabetic* OR drug* OR substance abuse* 
OR medication* OR prescription* OR prescribe* OR nutrition* OR 
maternal health OR (mother* ADJ2 health) OR side effect* OR adverse 
reaction* OR adverse effect* OR adverse event* OR hypertension OR 
blood pressure OR complication* OR exposure* OR expose* OR risk* 
OR factor* OR non-genetic OR nongenetic OR non-syndromic OR 
nonsyndromic OR environmental OR (maternal ADJ2 (illness* OR 
disease*)) OR sociodemographic* OR demographic* OR alcohol* OR 
ethanol OR teratogen* OR hyperglycemi* OR infection* OR CMV OR 
cytomegalovirus OR rubella OR herpes OR virus* OR syphilis OR 
influenza OR fever OR STI* OR STD* OR chlamydia OR anemia OR 
supplement* OR salicylate* OR sulfasalazine OR aspirin OR 
acetaminophen OR advanced age OR smoking OR smoked OR tobacco 
OR antibiotic* OR penicillin* OR ampicillin OR trimethoprim OR sulfa-
methoxazole OR hormone* OR progesterone OR contraceptive* OR 
progesto-gen* OR birth control OR assisted reproduct* OR cholesterol 
OR statin* OR lovastatin OR methotrexate OR tranexamic acid OR 
chloriazepoxide OR imipr-amine OR lithium OR dimenhydrinate OR 
fertility OR obesity OR BMI OR diet* OR education* OR income OR 
socioeconomic* Or cancer* OR epilepsy OR epileptic OR antiepileptic* 
OR anticonvulsant* OR acne OR retinoic acid
Limit 2010- ; exclude Medline journals
CINAHL 
(Ebsco)
Holoprosencephaly 1/11/2018 10–6 
duplicates = 
4 unique 
items
AND
Case* OR epidemiolog* OR report* OR inciden* OR occurrence OR 
surveillance OR Diabetes OR diabetic* OR drug* OR “substance 
abuse*” OR medication* OR prescription* OR prescribe* OR nutrition* 
OR “maternal health” OR (mother* N2 health) OR “side effect*” OR 
“adverse reaction*” OR “adverse effect*” OR “adverse event*” OR 
hypertension OR blood pressure OR complication* OR exposure* OR 
expose* OR risk* OR factor* OR non-genetic OR nongenetic OR non-
syndromic OR nonsyndromic OR environmental OR (maternal N2 
(illness* OR disease*)) OR sociodemographic* OR demographic* OR 
alcohol* OR ethanol OR teratogen* OR hyperglycemi* OR infection* 
OR CMV OR cytomegalovirus OR rubella OR herpes OR virus* OR 
syphilis OR influenza OR fever OR STI* OR STD* OR chlamydia OR 
anemia OR supplement* OR salicylate* OR sulfasalazine OR aspirin OR 
acetaminophen OR advanced age OR smoking OR smoked OR tobacco 
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OR antibiotic* OR penicillin* OR ampicillin OR trimethoprim OR 
sulfamethoxazole OR hormone* OR progesterone OR contraceptive* OR 
progestogen* OR “birth control” OR “assisted reproduct*” OR 
cholesterol OR statin* OR lovastatin OR methotrexate OR tranexamic 
acid OR chloriazepoxide OR imipramine OR lithium OR dimenhydrinate 
OR fertility OR obesity OR BMI OR diet* OR education* OR income 
OR socioeconomic* Or cancer* OR epilepsy OR epileptic OR 
antiepileptic* OR anticonvulsant* OR acne OR “retinoic acid”
Limit 2010- ; exclude Medline records
Cochrane 
library
Holoprosencephaly:ti,ab 1/11/2018 0
AND
(Case* OR epidemiolog* OR report* OR inciden* OR occurrence OR 
surveillance OR Diabetes OR diabetic* OR drug* OR “substance 
abuse*” OR medication* OR prescription* OR prescribe* OR nutrition* 
OR “maternal health” OR (mother* NEAR/2 health) OR “side effect*” 
OR “adverse reaction*” OR “adverse effect*” OR “adverse event*” OR 
hypertension OR blood pressure OR complication* OR exposure* OR 
expose* OR risk* OR factor* OR non-genetic OR nongenetic OR non-
syndromic OR nonsyndromic OR environmental OR (maternal NEAR/2 
(illness* OR disease*)) OR sociodemographic* OR demographic* OR 
alcohol* OR ethanol OR teratogen* OR hyperglycemi* OR infection* 
OR CMV OR cytomegalovirus OR rubella OR herpes OR virus* OR 
syphilis OR influenza OR fever OR STI* OR STD* OR chlamydia OR 
anemia OR supplement* OR salic-ylate* OR sulfasalazine OR aspirin 
OR acetaminophen OR advanced age OR smoking OR smoked OR 
tobacco OR antibiotic* OR penicillin* OR ampicillin OR trimethoprim 
OR sulfamethoxazole OR hormone* OR progesterone OR contraceptive* 
OR progestogen* OR “birth control” OR “assisted reproduct*” OR 
cholesterol OR statin* OR lovastatin OR methotrexate OR tranexamic 
acid OR chloriazepoxide OR imipramine OR lithium OR dimenhydrinate 
OR fertility OR obesity OR BMI OR diet* OR education* OR income 
OR socioeconomic* Or cancer* OR epilepsy OR epileptic OR 
antiepileptic* OR anticonvulsant* OR acne OR “retinoic acid”):ti,ab
Limit 2010- ;
Scopus Non-genetic risk factors for boloprosencephaly cited by 1/11/2018 23–11 
duplicates = 
12 unique 
items
OR
TITLE-ABS-KEY(Holoprosencephaly AND (Case* OR epidemiolog* 
OR report* OR inciden* OR occurrence OR surveillance OR Diabetes 
OR diabetic* OR drug* OR “substance abuse*” OR medication* OR 
prescription* OR prescribe* OR nutrition* OR “maternal health” OR 
(mother* W/2 health) OR “side effect*” OR “adverse reaction*” OR 
“adverse effect*” OR “adverse event*” OR hypertension OR “blood 
pressure” OR complication* OR exposure* OR expose* OR risk* OR 
factor* OR non-genetic OR nongenetic OR non-syndromic OR non-
syndromic OR environmental OR (maternal W/2 illness*) OR (maternal 
W/2 disease*) OR sociodemographic* OR demographic* OR alcohol* 
OR ethanol OR teratogen* OR hyperglycemi* OR infection* OR CMV 
OR cytomegalovirus OR rubella OR herpes OR virus* OR syphilis OR 
influenza OR fever OR STI* OR STD* OR chlamydia OR anemia OR 
supplement* OR salicylate* OR sulfasalazine OR aspirin OR 
acetaminophen OR advanced age OR smoking OR smoked OR tobacco 
OR antibiotic* OR penicillin* OR ampicillin OR trimethoprim OR 
sulfamethoxazole OR hormone* OR progesterone OR contraceptive* OR 
progestogen* OR “birth control” OR “assisted reproduct*” OR 
cholesterol OR statin* OR lovastatin OR methotrexate OR tranexamic 
acid OR chloriazepoxide OR imipramine OR lithium OR dimenhydrinate 
OR fertility OR obesity OR BMI OR diet* OR education* OR income 
OR socioeconomic* Or cancer* OR epilepsy OR epileptic OR 
antiepileptic* OR anticonvulsant* OR acne OR “retinoic acid”)) AND 
NOT INDEX(medline) AND NOT INDEX(embase)
Notes. Duplicates were identified using the Endnote automated “find duplicates” function with preference set to match on 
title, author and year, and removed from your Endnote library. There will likely be additional duplicates found that Endnote 
was unable to detect.
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FIGURE 1. 
Search strategy for identifying epidemiologic studies of nongenetic risk factors of 
holoprosencephaly since the 2010 review was conducted. * Johnson and Rasmussen (2010)
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